JNJ-1013

N/A

Report date: 2023/03/07 15:25:36
NME

Base Information

Drug NameJNJ-1013
Drug Alias NameJNJ-1013
ClassificationSmall molecules > Proteolysis-Targeting Chimera (PROTAC)
Mechanisms of ActionInterleukin-1 receptor-associated kinase 1 degraders
TargetsInterleukin-1 receptor-associated kinase 1
Therapy Area/IndicationsLymphoma, Large B-Cell, Diffuse
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesJohnson & Johnson
China Registration ClassN/A

Develop Information

Active CompaniesJohnson & Johnson
Inactive CompaniesN/A
Active IndicationsLymphoma, Large B-Cell, Diffuse
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A